NVS receives Breakthrough Therapy Designation (BTD) for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises in sickle cell disease
- Crizanlizumab is under development as a monthly infusion treatment for preventing pain in Crises (aka vaso-occlusive crises, or VOCs) in individuals with sickle cell disease (SCD)
- Sickle cell Crises is associated with increased morbidity and mortality, and is stimulated by multi-cell adhesion blocking blood flow.
- The FDA filing for crizanlizumab is expected in the 1st half of 2019
- Crizanlizumab was granted BTD for patients of all genotypes with sickle cell disease for the prevention of pain associated with VOCs.
- VOCs (sickle cell pain crises) are extremely painful and unpredictable occurrences that can lead to serious chronic and acute complications.
- Sickle cell pain crises happens when blood cells stick to each other and blood vessels causing blockages. By prevent or reducing the prevalence of blood cells sticking together NVS can potentially reduce the frequency that patients experience VOCs.
- On average each sickle cell patient is burdened by $1 million in healthcare related costs. The estimated annual cost for adults is over $30,000
- NVS is up 1.30% premarket.
Statement by Samit Hirawat, MD, Head, Novartis Oncology Global Drug Development:
“Painful sickle cell crises matter because they can disrupt patients’ lives, and often require hospital visits and medical attention…We look forward to working closely with the FDA over the coming months toward making crizanlizumab, a therapy that has the potential to prevent sickle cell pain crises, available in the US as soon as possible.”NVS press release
MS Money Moves and it’s Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.